NFKBIA deletion in glioblastomas

New England Journal of Medicine

Volumn 364, Issue 7, 2011, Pages 627-637

  Bredel, Markus ^a,b,c,d   Scholtens, Denise M ^c   Yadav, Ajay K ^c   Alvarez, Angel A ^b   Renfrow, Jaclyn J ^c   Chandler, James P ^c   Yu, Irene L Y ^a   Carro, Maria S ^a   Dai, Fangping ^a   Tagge, Michael J ^c   Ferrarese, Roberto ^a   Bredel, Claudia ^a   Phillips, Heidi S ^e   Lukac, Paul J ^c   Robe, Pierre A ^f,g   Weyerbrock, Astrid ^a   Vogel, Hannes ^d   Dubner, Steven ^c   Mobley, Bret ^d   He, Xiaolin ^c   Scheck, Adrienne C ^h   Sikic, Branimir I ^d   Aldape, Kenneth D ⁱ   Chakravarti, Arnab ^j   Harsh IV, Griffith R ^d   more..

^a UNIVERSITY OF FREIBURG   (Germany)

^b The University of Alabama at Birmingham   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e GENENTECH INC   (United States)

^f UNIVERSITY OF LIÈGE   (Belgium)

^g UTRECHT UNIVERSITY   (Netherlands)

^h BARROW NEUROLOGICAL INSTITUTE   (United States)

ⁱ UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^j OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; I KAPPA B KINASE ALPHA; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CELL VIABILITY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR CELL;

EID: 79951844223     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1006312     Document Type: Article

References (39)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507. [Erratum, N Engl J Med 2008;359:877.]
2. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
3. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-73.
4. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73. (Pubitemid 43357943)
5. Bredel M, Scholtens DM, Harsh GR, et al. A network model of a cooperative genetic landscape in brain tumors. JAMA 2009;302:261-75.
6. Yadav AK, Renfrow JJ, Scholtens DM, et al. Monosomy of chromosome 10 associated with dysregulation of epidermal growth factor signaling in glioblastomas. JAMA 2009;302:276-89.
7. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
8. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996;6:217-23.
9. Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010;17:98-110.
10. Habib AA, Chatterjee S, Park SK, Ratan RR, Lefebvre S, Vartanian T. The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B: identification of a novel receptor-tyrosine kinase signalosome. J Biol Chem 2001;276:8865-74.
11. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB. Epidermal growth factor (EGF) activates nuclear factor-kappaB through IkappaBalpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of IkappaBalpha. Oncogene 2007;26:7324-32. (Pubitemid 350115978)
12. Raychaudhuri B, Han Y, Lu T, Vogelbaum MA. Aberrant constitutive activation of nuclear factor kappaB in glioblastoma multiforme drives invasive phenotype. J Neurooncol 2007;85:39-47. (Pubitemid 47422655)
13. Nagai S, Washiyama K, Kurimoto M, Takaku A, Endo S, Kumanishi T. Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma. J Neurosurg 2002;96:909-17. (Pubitemid 34415406)
14. Bredel M, Bredel C, Juric D, et al. Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol 2006;24:274-87. (Pubitemid 46622056)
15. Tsunoda K, Kitange G, Anda T, et al. Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion. Brain Tumor Pathol 2005;22:79-87. (Pubitemid 44576317)
16. Bassères DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006;25:6817-30. (Pubitemid 44657854)
17. Spink CF, Gray LC, Davies FE, Morgan GJ, Bidwell JL. Haplotypic structure across the I kappa B alpha gene (NFKBIA) and association with multiple myeloma. Cancer Lett 2007;246:92-9. (Pubitemid 44959379)
18. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dörken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999;18:943-53. (Pubitemid 29086271)
19. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene 1999;18:3063-70. (Pubitemid 29261226)
20. Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999;94:3129-34. (Pubitemid 29512720)
21. Jungnickel B, Staratschek-Jox A, Bräuninger A, et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000;191:395-402.
22. Lake A, Shield LA, Cordano P, et al. Mutations of NFKBIA, encoding IkappaBalpha, are a recurrent finding in classical Hodgkin lymphoma but are not a unifying feature of non-EBV-associated cases. Int J Cancer 2009;125:1334-42.
23. Sjöblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74. (Pubitemid 44571966)
24. Gao J, Pfeifer D, He LJ, et al. Association of NFKBIA polymorphism with colorectal cancer risk and prognosis in Swedish and Chinese populations. Scand J Gastroenterol 2007;42:345-50.
25. Osborne J, Lake A, Alexander FE, Taylor GM, Jarrett RF. Germline mutations and polymorphisms in the NFKBIA gene in Hodgkin lymphoma. Int J Cancer 2005;116:646-51. (Pubitemid 41099203)
26. He Y, Zhang H, Yin J, et al. IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis 2009;30:1916-22.
27. Bu H, Rosdahl I, Sun XF, Zhang H. Importance of polymorphisms in NF-kappaB1 and NF-kappaBIalpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol 2007;133:859-66. (Pubitemid 350218912)
28. Liu X, Yu H, Yang W, Zhou X, Lu H, Shi D. Mutations of NFKBIA in biopsy specimens from Hodgkin lymphoma. Cancer Genet Cytogenet 2010;197:152-7.
29. Parker KM, Ma MH, Manyak S, et al. Identification of polymorphisms of the IkappaBalpha gene associated with an increased risk of multiple myeloma. Cancer Genet Cytogenet 2002;137:43-8.
30. Kapoor GS, Zhan Y, Johnson GR, O'Rourke DM. Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells. Mol Cell Biol 2004;24:823-36. (Pubitemid 38057932)
31. Stupp R, Dietrich PY, Ostermann Kraljevic S, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-82. (Pubitemid 34177445)
32. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
33. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. (Pubitemid 40349502)
34. Everhard S, Tost J, El Abdalaoui H, et al. Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 2009;11:348-56.
35. Mikeska T, Bock C, El-Maarri O, et al. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 2007;9:368-81. (Pubitemid 47305073)
36. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955;19:251-3.
37. Lee Y, Scheck AC, Cloughesy TF, et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 2008;1:52.
38. Fulci G, Labuhn M, Maier D, et al. p53 Gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma. Oncogene 2000;19:3816-22. (Pubitemid 30621189)
39. Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res 2002;62:4307-15. (Pubitemid 34827287)